News in brief

Australian institute to study ChromaDex's Niagen ingredient in mitochondrial respiratory conditions

Niagen supports mitochondrial health, ChromaDex says.

ChromaDex Corp. announced an agreement to supply its Niagen nicotinamide riboside ingredient to the Murdoch Children’s Research Institute in Australia to enable researchers there to study the ingredient’s effects in cellular and animal models of mitochondrial respiratory diseases.

Niagen is the only commercially available form of nicotinamide riboside (NR), which is a naturally occurring vitamin B3 derivative found in milk. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell.  NAD+ is an important cellular co-factor for improvement of mitochondrial performance and energy.  NAD+ is essential in supporting healthy cellular metabolism including the efficient conversation of blood glucose into energy. 

Dr. David Thorburn, Mitochondrial Research group head at Murdoch Childrens Research Institute, together with Dr. Ann Frazier and Dr. Bi-Xia Ke, and supported by a grant from the Australian Mitochondrial Disease Foundation, will study the response to NR in mouse models with mitochondrial Complex I deficiency and in a range of human and mouse cell lines with impaired mitochondrial function.

In addition to Niagen, ChromaDex also supplies pTeroPure pterostilbene; ProC3G, a natural black rice containing cyanidin-3-glucoside; and Purenergy, a caffeine-pTeroPure co-crystal.  The company also performs analytical testing services and coslting services via its Spherix Consulting subsidiary.

Related News

ChromaDex’s new deal with Brazilian Biosciences National Laboratory could lead to ‘rapid commercialization of novel natural products’

ChromaDex’s new deal with Brazilian Biosciences National Laboratory could lead to ‘rapid commercialization of novel natural products’

ChromaDex signs marketing deal with consulting firm

ChromaDex signs marketing deal with consulting firm

DSM Venturing strategically invests in ChromaDex

DSM Venturing strategically invests in ChromaDex

ChromaDex expands capabilities with Spherix Consulting acquisition

ChromaDex expands capabilities with Spherix Consulting acquisition

HPN's new product with Chromadex’s Niagen targets neuroprotection for contact sports

HPN's new product with Chromadex’s Niagen targets neuroprotection for contact sports

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.